Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 15, 2012

Bruker Opens Center of Excellence in Moscow

  • Bruker opened an applications and customer support Center of Excellence in Moscow to provide clients with scientific instruments for life-science and analytical applications based on NMR, X-ray analysis, mass spectrometry, chromatography, molecular spectroscopy, and AFM microscopy. The new center brings together the expertise of a number of Bruker divisions to provide support for sales, applications, service requests, and collaborations in Russia.

    “The new Bruker Center of Excellence offers all of our Russian and CIS customers additional opportunities to explore numerous high-performance analytical instruments and cutting-edge applied solutions with our high level experts here in Moscow,” comments Nikolay Yakovlev, general director of the firm’s Russian operation. “This investment provides us with the infrastructure, high-performance systems, and highly qualified staff to provide comprehensive scientific and engineering expertise across many life science and analytical technologies for the benefit of our Russian academic, government, clinical, and industrial customers.”

    Bruker and its wholly owned subsidiaries design, manufacture, service, and market proprietary life science and materials research systems based on technology platforms including magnetic resonance, mass spectrometry, gas chromatography, X-ray, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology, as well as infrared and Raman molecular spectroscopy. The firm reported overall revenues of $1.65 billion in calendar 2011, up 26.6% on 2010 figures. Revenues from the sale of scientific instruments and related after-market revenues division reached $1.55 billion in 2011, up $26.9%. 



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »